| Public title (as per ICTRP) | Scientific title (as per ICTRP) | Trial identifier |
|---|---|---|
| A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI) between 27 kg/m2 and 40 kg/m2 - X 112 dose-finidng | A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI) between 27 kg/m2 and 40 kg/m2 - X 112 dose-finidng | EUCTR2009-010116-15-DE |
| A clinical trial to assess efficacy and safety of Alvalin® (active agent) vs. placebo (inactive substance) in 265 obese patients/group with a body mass index (BMI) between 30 and 45 kg/m2. Neither the investigator nor the participant are aware of the nature of the treatment the participant is receiving. The trial is conducted in several trial centres. | A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) between 30 and 45 kg/m2 | EUCTR2012-003426-24-DE |
